Advancing Treatments for Rare Eye Diseases in Europe
Restore Vision is a project funded by the European Commission aiming to develop and test new treatments for 7 rare eye diseases (REDs). The consortium joins 10 European key players on rare eye diseases and is led by University of Galway.
About Restore Vision
+30 million
people suffer from blindness and visual impairment
About Restore Vision
Over the the next 4 years (2023-2027) the Restore Vision consortium will explore new treatments for 7 REDs by repurposing existing generic drugs, developing new therapeutic compounds, and conducting pioneering clinical trials to ensure their safety and effectiveness.
Learn more about our work
Project in numbers
0
Years (2023-2027)
0
Partners
0
mil EUR in funding
0
EU Countries
0
Work packages
Watch our video:
News
Read Restore Vision’s latest news.
08 May 2025
Join our Patients Working Group!
Are you living with a rare eye disease? Or are you a caretaker of someone who is? Join the Patients Working Group of the international research project Restore Vision! [Available in EN, IT, ES, FR, SE, DE]
Read more
08 May 2025
New study: mineralocorticoid receptor antagonism improves corneal integrity in a rat model of limbal stem cell deficiency
In this new study, our team at INSERM, explored whether mineralocorticoid receptor antagonists (MRAs)—commonly used for heart and kidney conditions—could aid corneal repair in limbal stem cell deficiency (LSCD), a rare and difficult-to-treat eye disease.
Read more
01 May 2025
New study: the role of Mesenchymal Stromal Cells and Apoptotic Bodies in immune regulation
Research has shown that MSC-derived ApoBDs can help regulate the immune system, however they have not been studied as much as smaller extracellular vesicles. To fill in the gap, our team at Galway conducted a study to explore the therapeutic potential of large and small ApoBDs.
Read more
06 February 2025
Healing the cornea: the therapeutic potential of Mesenchymal Stromal Cells and their Extracellular Vesicles
In this new article, our team at the University of Galway reviewed and analysed current research on the use of MSCs and MSC-EVs in treating corneal diseases.
Read more
30 January 2025
New article: Are inactive ingredients in eye drops safe? A closer look at excipients safety, function an regulation.
Restore Vision has conducted the first comprehensive review of FDA-approved excipients in ophthalmic medications, examining their roles, safety, and the regulatory pathways required for approval for human use.
Read more
Interested in Restore vision?
Stay informed about our efforts to combat rare eye diseases and bring new hope to those affected by visual impairment by subscribing to our newsletter for updates on our latest treatments and research.